Discussion {#s3}
==========

Abiraterone acetate is active and approved for use in patients with metastatic castration-resistant prostate cancer \[[@B1], [@B2]\], but resistance does develop, and the mechanism of drug resistance is under active investigation \[[@B3]\]. Preclinical studies have shown AK as a potential target for advanced PCa, especially for PCa with neuroendocrine differentiation. We investigated whether the addition of alisertib, an AK inhibitor, to an AP regimen was tolerable and effective to reverse resistance to abiraterone.

The trial was terminated early because of toxicity and lack of clinical benefit. The first three patients in cohort 1 (30 mg b.i.d., days 1--7 every 21 days) did not experience a DLT. Two patients experienced DLTs in cohort 2 (40 mg level) (fatigue with memory impairment or neutropenic fever), resulting in dose de-escalation Three additional patients were treated at 30 mg b.i.d., and two developed DLTs (neutropenia and diarrhea/mucositis). Evaluation of side-effect profile among the nine patients demonstrated poor tolerability of alisertib and abiraterone/prednisone combination. Bone marrow suppression is a known side effect from alisertib \[[@B4], [@B5]\], but the rate of grade 3/4 toxicities was higher in our study compared with others. It is important to note that previous studies used alisertib as monotherapy in solid tumors. To improve patient tolerance, it might be reasonable to use a different dose and schedule for patients with relatively slow-growing tumors such as prostate cancer.

The efficacy is difficult to assess in this phase I trial. Three patients were taken off the study because of disease progression. Seven (of 9) patients had an increase in PSA during the study. Four (of 9) patients in the trials had ≥5 CTCs at baseline, but no conversion was observed at the end of therapy. Mean duration on the study was 2.5 months. These results suggest an unfavorable efficacy-to-toxicity ratio for this combination. The trial was prematurely terminated, and the phase II portion was not performed.

From measuring the total testosterone and DHEA levels during the study, we believe alisertib does not interfere with the ability of abiraterone to inhibit biosynthesis of androgens. For neuroendocrine biomarkers, we observed three (of nine) patients who had a sustained decreased in chromogranin A levels and four (of nine) patients who had a decrease in neuron-specific enolase levels. The significance of these changes is not clear, given the small sample size of the study. Fluorescence in situ hybridization analysis of collected CTCs did not demonstrate AK amplification. Further study is certainly needed to make any conclusions.

In summary, adding alisertib to abiraterone regimen seems intolerable in mCRPC. The optimal dose and schedule of alisertib could not be determined. There was no clear signal indicating that alisertib might be beneficial for patients with mCRPC progressing on abiraterone, and further development of this treatment combination is not warranted.

Trial Information {#s4}
=================

DiseaseProstate cancerStage of disease / treatmentMetastatic/advancedPrior Therapy1 prior regimenType of study - 1Phase IType of study - 23+3 dose escalationPrimary EndpointSafetyPrimary EndpointMaximum tolerated doseSecondary EndpointPSA kinetics after alisertib is added to abiraterone and prednisone regimenSecondary EndpointBaseline and post-therapy CTCs enumerationSecondary EndpointBaseline and post-therapy chromogranin A and neuron-specific enolase levelsAdditional Details of Endpoints or Study Design1. DHEA and testosterone kinetics after alisertib2. Aurora kinase A gene amplification statusInvestigator\'s AnalysisPoorly tolerated/not feasible

Drug Information {#s5}
================

Drug 1Generic/working nameMLN 8237Trade nameAlisertibCompany nameMillennium: The Takeda Oncology CompanyDrug typeSmall moleculeDrug classMitotic - Aurora kinaseDosemilligrams (mg) per flat doseRouteoral (p.o.)Schedule of administrationDose Level −1: Alisertib, 20 mg p.o. b.i.d., days 1--7 every 21 daysDose Level 0 (starting): Alisertib, 30 mg p.o. b.i.d., days 1--7 every 21 daysDose Level 1: Alisertib, 40 mg p.o. b.i.d., days 1--7 every 21 daysDose Level 2: Alisertib, 50 mg p.o. b.i.d., days 1--7 every 21 daysThe first cohort was treated at dose level 0 with no DLTs. The second cohort was treated at dose level 1 with two DLTs. Per protocol, dose de-escalation was to level 0 with three additional subjects.

Patient Characteristics {#s6}
=======================

Number of patients, male9Number of patients, female0StageStage IV, MetastaticAgeMedian (range): 68 (62--82)Number of prior systemic therapiesMedian (range): 1 (1--2)Performance Status: ECOG0 --- 71 --- 22 --- 03 --- 0Unknown --- 0OtherNot collectedCancer types or histologic subtypesAdenocarcinoma of prostate: 9

Primary Assessment Method {#s7}
=========================

Number of patients screened9Number of patients enrolled9Number of patients evaluable for toxicity9Number of patients evaluated for efficacy9Evaluation methodClinic visit at 12 weeks or progression: CT\\MRI Abd and Pelvis; CT of chest or CXR; Bone Scan; PSA; Androgen PanelResponse assessment CR0Response assessment PR0Response assessment SD0Response assessment PD*n* = 3Response assessment OTHER*n* = 6

Adverse Events {#s8}
==============

Serious Adverse Events {#s9}
======================

Dose-Limiting Toxicities {#s10}
========================

Assessment, Analysis, and Discussion {#s12}
====================================

CompletionStudy terminated before completionTerminated reasonToxicityInvestigator's assessmentPoorly tolerated/not feasible

Abiraterone acetate is active and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) \[[@B1], [@B2]\]. Unfortunately, disease progression inevitably occurs, and patients require additional therapy, which remains an unmet medical need. The mechanism of resistance to abiraterone is not clear and is still under active investigation \[[@B3]\]. It is widely accepted that prostate cancer (PCa) is composed of heterogeneously distinct cell subtypes, including neuroendocrine prostate cancer (NEPC). NEPC is generally considered an aggressive and lethal variant of PCa that most commonly arises from existing PCa \[[@B6]\]. Clinically, NEPC often has high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) \[[@B7]\]. The presence of the neuroendocrine (NE) tumor subpopulation can be gauged noninvasively by measuring circulating levels of secretory products, primarily CgA \[[@B8]\]. Increased plasma CgA was observed in 64.3% of patients with CRPC \[[@B9]\]. Increased NSE was seen in 35% of patients \[[@B10]\]. These NEPC can be considered to be castration-resistant and androgen receptor (AR)-independent because AR signaling is not a key player for survival of these cells \[[@B11], [@B12]\]. The development of the NE features (transformation) in androgen-deprived conditions may contribute to castrate resistance and/or abiraterone resistance. Molecularly, Aurora Kinase (AK) (and concurrent *MYCN* oncogene) amplification was identified by fluorescence in situ hybridization (FISH) in 75% of primary PCa of patients with NEPC (\>95% cells) \[[@B11]\]. By using tissue biopsies from metastatic sites, up to 53% metastatic PCa were found to harbor AK amplification \[[@B11]\].

In vitro studies support the fact that there is a functional relationship between AK and PCa: (a) AK is overexpressed in PCa, especially in anti-androgen-resistant PCa \[[@B13], [@B14]\]; (b) AK phosphorylates and interacts with AR, enhancing AR DNA binding \[[@B15]\]; (c) AK induces cell growth in the presence and absence of androgen; (d) AK induces/enhances AR activity and potentiates androgen action in AR; and (e) targeting AK reverses the androgen-independent phenotype in vitro \[[@B15]\]. Features of mCRPC likely include AK (and concurrent MYCN) amplification/overexpression with NE phenotype. AK is potentially an important drugable target for CRPC with or without neuroendocrine differentiation. Therefore, we investigated whether mCRPC is sensitive to AK suppression by alisertib, especially in the subgroup of patients with neuroendocrine phenotype. We hypothesized that adding alisertib to the existing androgen-deprivation therapy regimen may reverse the resistance to abiraterone.

We designed a phase I/II, open-label, single-institution trial to determine the safety and efficacy of the AK inhibitor alisertib when given in combination with abiraterone plus prednisone (AP). In the phase I portion, we evaluated the maximum tolerated dose of alisertib. In the phase II study, we planned to evaluate the proportion of patients who had no disease progression after alisertib is added to abiraterone and prednisone.

The trial was terminated early because of toxicity and lack of clinical benefit. The first three patients in cohort 1 (30 mg b.i.d., days 1--7 every 21 days) did not experience a dose-limiting toxicity (DLT). Two patients experienced DLTs in cohort 2 (fatigue with memory impairment and neutropenic fever), resulting in dose de-escalation. Three additional patients were treated at 30 mg b.i.d., and two developed DLTs (neutropenia and diarrhea/mucositis). Evaluation of the side-effect profile among the nine patients demonstrated poor tolerability of the alisertib and abiraterone/prednisone combination. Five (of 9) patients required a treatment delay. Bone marrow suppression is a known side effect from alisertib \[[@B4], [@B5]\], and although the rate of grade 3/4 toxicities was higher in our study compared with others, it is important to note that previous studies used alisertib as monotherapy. To improve patient tolerance, it might be reasonable to use a different dose and schedule for patients with relatively slow-growing tumors such as prostate cancer.

The efficacy of alisertib and abiraterone is difficult to assess in this phase I trial. Three patients were taken off the study because of disease progression. Seven (of 9) patients had an increase in prostate-specific antigen (PSA) during the study. The effect of alisertib on circulating tumor cell (CTC) enumeration before and after treatment was also measured. Four (of 9) patients in the trials had ≥5 CTCs at baseline, but no conversion was observed at the end of therapy. These results suggest an unfavorable efficacy to toxicity ratio of alisertib with abiraterone and prednisone. Therefore, the trial was terminated earlier, and the phase II portion was not performed.

We looked at the possible pharmacodynamic interactions between alisertib and abiraterone. The addition of alisertib did not significantly affect the total testosterone and dehydroepiandrosterone (DHEA) levels. This suggests that alisertib does not interfere with the ability of abiraterone to inhibit the biosynthesis of androgens.

For neuroendocrine biomarkers, we observed 3 (of 9) patients who had a sustained decreased in chromogranin A levels and 4 (of 9) patients who had a decrease in neuron-specific enolase levels. The significance of these changes is not clear, given the small sample size of the study. FISH analysis of collected CTCs did not demonstrate AK amplification. Further study is certainly needed to make any conclusions.

In summary, adding alisertib to an abiraterone regimen seems intolerable in mCRPC. The optimal dose and schedule of alisertib could not be determined. There was no clear signal indicating that alisertib might be beneficial for patients with mCRPC progressing on abiraterone, and further development of this treatment combination is not warranted.
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![Effects of alisertib on androgen synthesis. **(A)**: DHEA levels during the study treatment. **(B)**: Total testosterone levels during the study treatment.\
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Dose-limiting toxicities
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Changes of CgA and NSE levels after treatment with alisertib
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